Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (AVXL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AVXL · as of Mar 31, 2025
Ownership Breakdown
197
Institutional Holders
▲ 12 vs Q4
$269.18M
Total Inst. Value
▼ $47.00M vs Q4
92.67M
Shares Outstanding
freeFloat 96.88%
31.37M
13F Shares Held
▲ 1.80M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AVXL largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.70M | 7.88% | 7.88% | $57.52B | May 2, 2025 | ▲ 151.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 4.90M | 5.76% | 5.76% | $42.06B | May 9, 2025 | ▲ 221.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 3.21M | 3.78% | 3.78% | $27.58B | May 15, 2025 | ▲ 802.3K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.96M | 2.31% | 2.31% | $16.86B | May 13, 2025 | ▲ 89.9K |
NWAM LLC biological products, (no diagnostic substances) | 1.00M | 1.18% | 1.18% | $8.58B | May 5, 2025 | ▲ 87.3K |
MORGAN STANLEY biological products, (no diagnostic substances) | 864.7K | 1.02% | 1.02% | $7.42B | May 15, 2025 | ▼ 39.4K |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 860.1K | 1.01% | 1.01% | $7.38B | May 15, 2025 | ▲ 83.2K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 787.1K | 92.52% | 92.52% | $6.75B | May 14, 2025 | ▼ 347.6K |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 734.7K | 86.36% | 86.36% | $6.30B | May 13, 2025 | ▲ 27.8K |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC biological products, (no diagnostic substances) | 669.9K | 78.74% | 78.74% | $5.75B | Sep 15, 2025 | ▼ 7.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
29
Increased
+3.46M shares7
New Positions
first time holders12
Decreased
−677.8K shares0
Sold Out
fully exitedNet shares change (top 50)
+2.78M
+3.46M / −677.8K
Net new holders
+24
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AVXL insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
MISSLING CHRISTOPHER U President and CEO | Jan 6, 2026 | Award | 125,000 | $8.58 | $1.07M | 125.0K | Form 4 ↗ |
Boenisch Sandra PFO & Treasurer | Jan 6, 2026 | Award | 12,500 | $8.58 | $107.3K | 12.5K | Form 4 ↗ |
Boenisch Sandra PFO & Treasurer | Oct 2, 2025 | Award | 12,500 | $5.36 | $67.0K | 25.0K | Form 4 ↗ |
MISSLING CHRISTOPHER U President and CEO | Oct 2, 2025 | Award | 125,000 | $5.36 | $670.0K | 250.0K | Form 4 ↗ |
MISSLING CHRISTOPHER U President and CEO | Sep 11, 2025 | Tax Withhold | 145,048 | $9.58 | $1.39M | 1.51M | Form 4 ↗ |
Boenisch Sandra PFO & Treasurer | Aug 20, 2025 | Award | 12,500 | $8.58 | $107.3K | 12.5K | Form 4 ↗ |
MISSLING CHRISTOPHER U President and CEO | Aug 20, 2025 | Award | 125,000 | $8.58 | $1.07M | 125.0K | Form 4 ↗ |
Thomas Steffen director | Jun 5, 2025 | Tax Withhold | 11,349 | $7.75 | $88.0K | 43.7K | Form 4 ↗ |
Boenisch Sandra PFO & Treasurer | Apr 28, 2025 | Award | 12,500 | $8.57 | $107.1K | 12.5K | Form 4 ↗ |
MISSLING CHRISTOPHER U President and CEO | Apr 28, 2025 | Award | 125,000 | $8.57 | $1.07M | 125.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Anavex Life Sciences Corp. (AVXL) is primarily owned by institutional investors, who hold approximately 33.9% of total shares outstanding. Company insiders own approximately 3.12%, while retail and public investors account for the remaining 63.03%.
The largest institutional shareholder of Anavex Life Sciences Corp. is BLACKROCK, INC., holding approximately 6.70 million shares — equal to 7.88% of outstanding shares — as of March 31, 2025.
A total of 197 institutional investors currently hold AVXL stock, with a combined institutional value of approximately $269,178,873 as of the most recent 13F filing period.
Frequently asked questions
AVXL ownershipAnavex Life Sciences Corp. (AVXL) is primarily owned by institutional investors, who hold approximately 33.9% of shares. The largest shareholder is BLACKROCK, INC. with a 7.88% stake. Company insiders hold 3.12%. Data sourced from SEC Form 13F as of March 31, 2025.